Dear Editors, Latent tuberculosis infection (LTBI) is not uncommon among renal transplant candidates (RTC) [1]. Rifapentine/isoniazid (RPT/INH) administered for 12 weeks is one of the first-line treatments for LTBI [1], and we have recently showed that it is associated with higher completion rates than INH monotherapy for 9 months [2].One theoretical concern in RTC is that RPT can decrease the efficacy of certain antihypertensive drugs (AHD) through the induction of cytochrome P (CYP) 3A4-CYP2C9 [3]. Namely, RPT can accelerate the metabolism of beta-and/or alpha-blockers, calcium channel blockers, and angiotensin receptor blockers [3,4].To explore the impact of RPT on blood pressure (BP) control, we retrospectively reviewed medical records on 37 adult RTC with baseline BP of <140/ 90 mmHg who were started on RPT/INH for LTBI between March 2012 and February 2015. Only patients who were on AHD that could interact with RPT were included. All the patients were diagnosed by a positive QuantiFERON-TB gold in-tube test. Patients received weekly RPT 900 mg (if weight >50 kg) and INH 15 mg/kg (900 mg max) and daily pyridoxine for 12 weeks. Potential drug-drug interactions (DDI) between RPT and AHD were identified by Lexicomp â Lexi-Interact TM Online software [4]. We evaluated the incidence and onset of severe hypertension (≥180/ 110 mmHg) after starting RPT/INH. Patients had their BP monitored at home and dialysis, and they were also asked about their BP control in each clinic visit. All patients had at least one follow-up visit.